Published in Viruses on August 21, 2014
A Conserved HIV-1-Derived Peptide Presented by HLA-E Renders Infected T-cells Highly Susceptible to Attack by NKG2A/CD94-Bearing Natural Killer Cells. PLoS Pathog (2016) 0.93
Variable processing and cross-presentation of HIV by dendritic cells and macrophages shapes CTL immunodominance and immune escape. PLoS Pathog (2015) 0.82
In vitro evaluation of digestive and endolysosomal enzymes to cleave CML-modified Ara h 1 peptides. Food Sci Nutr (2015) 0.75
Analysis of Major Histocompatibility Complex-Bound HIV Peptides Identified from Various Cell Types Reveals Common Nested Peptides and Novel T Cell Responses. J Virol (2016) 0.75
HIV evolution: CTL escape mutation and reversion after transmission. Nat Med (2004) 10.21
Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature (2004) 9.53
Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature (2011) 9.30
Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med (2009) 7.33
Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses. J Exp Med (2001) 6.51
Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52
HIV and SIV CTL escape: implications for vaccine design. Nat Rev Immunol (2004) 5.18
Immune selection for altered antigen processing leads to cytotoxic T lymphocyte escape in chronic HIV-1 infection. J Exp Med (2004) 4.52
Adaptation of HIV-1 to human leukocyte antigen class I. Nature (2009) 4.24
Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection. J Virol (2004) 4.20
HLA Alleles Associated with Delayed Progression to AIDS Contribute Strongly to the Initial CD8(+) T Cell Response against HIV-1. PLoS Med (2006) 4.19
Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat Med (2006) 4.14
Escape and compensation from early HLA-B57-mediated cytotoxic T-lymphocyte pressure on human immunodeficiency virus type 1 Gag alter capsid interactions with cyclophilin A. J Virol (2007) 3.93
ERAAP customizes peptides for MHC class I molecules in the endoplasmic reticulum. Nature (2002) 3.72
Confronting complexity: real-world immunodominance in antiviral CD8+ T cell responses. Immunity (2006) 3.67
Determinants of human immunodeficiency virus type 1 escape from the primary CD8+ cytotoxic T lymphocyte response. J Exp Med (2004) 3.48
The ER aminopeptidase ERAP1 enhances or limits antigen presentation by trimming epitopes to 8-9 residues. Nat Immunol (2002) 3.45
Concerted peptide trimming by human ERAP1 and ERAP2 aminopeptidase complexes in the endoplasmic reticulum. Nat Immunol (2005) 3.39
Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms. Science (2013) 3.27
A Blueprint for HIV Vaccine Discovery. Cell Host Microbe (2012) 3.27
Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat Immunol (2005) 3.23
Transmission of HIV-1 Gag immune escape mutations is associated with reduced viral load in linked recipients. J Exp Med (2008) 3.20
Immune clearance of highly pathogenic SIV infection. Nature (2013) 3.15
Dissecting the multifactorial causes of immunodominance in class I-restricted T cell responses to viruses. Immunity (2000) 2.94
Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell (2013) 2.88
Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method. BMC Bioinformatics (2007) 2.83
Pathways of antigen processing. Annu Rev Immunol (2013) 2.82
Naturally processed viral peptides recognized by cytotoxic T lymphocytes on cells chronically infected by human immunodeficiency virus type 1. J Exp Med (1994) 2.81
HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates. Proc Natl Acad Sci U S A (2005) 2.61
Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate. J Biol Chem (2006) 2.59
A major role for TPPII in trimming proteasomal degradation products for MHC class I antigen presentation. Immunity (2004) 2.53
An essential role for tripeptidyl peptidase in the generation of an MHC class I epitope. Nat Immunol (2003) 2.38
Coordinate linkage of HIV evolution reveals regions of immunological vulnerability. Proc Natl Acad Sci U S A (2011) 2.37
Variable fitness impact of HIV-1 escape mutations to cytotoxic T lymphocyte (CTL) response. PLoS Pathog (2009) 2.36
Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus- and HIV-1-specific T cell responses. J Immunol (2003) 2.34
Modeling the MHC class I pathway by combining predictions of proteasomal cleavage, TAP transport and MHC class I binding. Cell Mol Life Sci (2005) 2.32
Immunoproteasome assembly: cooperative incorporation of interferon gamma (IFN-gamma)-inducible subunits. J Exp Med (1998) 2.32
Flanking sequences influence the presentation of an endogenously synthesized peptide to cytotoxic T lymphocytes. J Exp Med (1992) 2.29
The sizes of peptides generated from protein by mammalian 26 and 20 S proteasomes. Implications for understanding the degradative mechanism and antigen presentation. J Biol Chem (1999) 2.29
HIV-1 group M conserved elements vaccine. PLoS Pathog (2007) 2.28
Immunoproteasomes shape immunodominance hierarchies of antiviral CD8(+) T cells at the levels of T cell repertoire and presentation of viral antigens. J Exp Med (2001) 2.28
New paradigms for HIV/AIDS vaccine development. Annu Rev Med (2011) 2.21
Presentation of exogenous antigens on major histocompatibility complex (MHC) class I and MHC class II molecules is differentially regulated during dendritic cell maturation. J Exp Med (2003) 2.16
Impaired processing and presentation of cytotoxic-T-lymphocyte (CTL) epitopes are major escape mechanisms from CTL immune pressure in human immunodeficiency virus type 1 infection. J Virol (2004) 2.12
MHC affinity, peptide liberation, T cell repertoire, and immunodominance all contribute to the paucity of MHC class I-restricted peptides recognized by antiviral CTL. J Immunol (1997) 2.12
Conflicting selective forces affect T cell receptor contacts in an immunodominant human immunodeficiency virus epitope. Nat Immunol (2006) 2.11
Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev (2011) 2.09
26S proteasomes and immunoproteasomes produce mainly N-extended versions of an antigenic peptide. EMBO J (2001) 2.09
Coping with viral diversity in HIV vaccine design. PLoS Comput Biol (2007) 2.01
24 hours in the life of HIV-1 in a T cell line. PLoS Pathog (2013) 1.89
Post-proteasomal antigen processing for major histocompatibility complex class I presentation. Nat Immunol (2004) 1.83
Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance. Nat Immunol (2009) 1.83
Cathepsin S activity regulates antigen presentation and immunity. J Clin Invest (1998) 1.76
MHC class II epitope predictive algorithms. Immunology (2010) 1.72
Portable flanking sequences modulate CTL epitope processing. J Clin Invest (2007) 1.72
Characterizing the N-terminal processing motif of MHC class I ligands. J Immunol (2008) 1.68
Immunoproteasomes largely replace constitutive proteasomes during an antiviral and antibacterial immune response in the liver. J Immunol (2001) 1.66
Identification of T. gondii epitopes, adjuvants, and host genetic factors that influence protection of mice and humans. Vaccine (2010) 1.61
Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1. Mol Ther (2013) 1.61
Interferon-gamma can stimulate post-proteasomal trimming of the N terminus of an antigenic peptide by inducing leucine aminopeptidase. J Biol Chem (1998) 1.60
Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice. J Clin Invest (2010) 1.58
ER aminopeptidases generate a unique pool of peptides for MHC class I molecules. Nat Immunol (2001) 1.56
Emerging strategies to deplete the HIV reservoir. Curr Opin Infect Dis (2014) 1.56
Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. Blood (2004) 1.54
Abrogation of CTL epitope processing by single amino acid substitution flanking the C-terminal proteasome cleavage site. J Immunol (2000) 1.52
An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc Natl Acad Sci U S A (1998) 1.50
Pathway for degradation of peptides generated by proteasomes: a key role for thimet oligopeptidase and other metallopeptidases. J Biol Chem (2004) 1.50
Identification of cryptic MHC I-restricted epitopes encoded by HIV-1 alternative reading frames. J Exp Med (2004) 1.48
Engineering synthetic vaccines using cues from natural immunity. Nat Mater (2013) 1.48
Plumbing the sources of endogenous MHC class I peptide ligands. Curr Opin Immunol (2006) 1.47
PAProC: a prediction algorithm for proteasomal cleavages available on the WWW. Immunogenetics (2001) 1.44
IRAP identifies an endosomal compartment required for MHC class I cross-presentation. Science (2009) 1.43
Internalization and endosomal degradation of receptor-bound antigens regulate the efficiency of cross presentation by human dendritic cells. Blood (2012) 1.43
An algorithm for the prediction of proteasomal cleavages. J Mol Biol (2000) 1.43
ERAAP synergizes with MHC class I molecules to make the final cut in the antigenic peptide precursors in the endoplasmic reticulum. Immunity (2006) 1.43
The cytosolic endopeptidase, thimet oligopeptidase, destroys antigenic peptides and limits the extent of MHC class I antigen presentation. Immunity (2003) 1.36
Optimizing vaccine design for cellular processing, MHC binding and TCR recognition. Tissue Antigens (2002) 1.31
MAPPP: MHC class I antigenic peptide processing prediction. Appl Bioinformatics (2003) 1.31
Sequential broadening of CTL responses in early HIV-1 infection is associated with viral escape. PLoS One (2007) 1.30
Characterization of the MHC class I cross-presentation pathway for cell-associated antigens by human dendritic cells. Blood (2003) 1.29
Protective efficacy of serially up-ranked subdominant CD8+ T cell epitopes against virus challenges. PLoS Pathog (2011) 1.27
CD8 T cell response and evolutionary pressure to HIV-1 cryptic epitopes derived from antisense transcription. J Exp Med (2010) 1.27
Viral evolution and escape during acute HIV-1 infection. J Infect Dis (2010) 1.26
Major histocompatibility complex class I-presented antigenic peptides are degraded in cytosolic extracts primarily by thimet oligopeptidase. J Biol Chem (2001) 1.26
Antigen delivery to early endosomes eliminates the superiority of human blood BDCA3+ dendritic cells at cross presentation. J Exp Med (2013) 1.25
Antigen processing by nardilysin and thimet oligopeptidase generates cytotoxic T cell epitopes. Nat Immunol (2010) 1.24
Getting to first base in proteasome assembly. Cell (2009) 1.22
CD8+ T cell epitope-flanking mutations disrupt proteasomal processing of HIV-1 Nef. J Immunol (2005) 1.21
Immunoproteasomes down-regulate presentation of a subdominant T cell epitope from lymphocytic choriomeningitis virus. J Immunol (2004) 1.21
Dendritic cells up-regulate immunoproteasomes and the proteasome regulator PA28 during maturation. Eur J Immunol (1999) 1.20
Point mutation flanking a CTL epitope ablates in vitro and in vivo recognition of a full-length viral protein. J Immunol (1997) 1.20
Activation of HIV-1 specific CD4 and CD8 T cells by human dendritic cells: roles for cross-presentation and non-infectious HIV-1 virus. AIDS (2002) 1.19
A genome-to-genome analysis of associations between human genetic variation, HIV-1 sequence diversity, and viral control. Elife (2013) 1.19
Viral adaptation to immune selection pressure by HLA class I-restricted CTL responses targeting epitopes in HIV frameshift sequences. J Exp Med (2010) 1.19
Cutting edge: class I presentation of host peptides following HIV infection. J Immunol (2003) 1.18
The human 26 S and 20 S proteasomes generate overlapping but different sets of peptide fragments from a model protein substrate. J Biol Chem (2000) 1.15
Escape mutations alter proteasome processing of major histocompatibility complex class I-restricted epitopes in persistent hepatitis C virus infection. J Virol (2005) 1.15
Cathepsin S controls MHC class II-mediated antigen presentation by epithelial cells in vivo. J Immunol (2005) 1.15